Highest-materiality recent filing
Solana increases ATM offering capacity from $92.8M to $250.0M via amended sales agreement
Amended Sales Agreement with Clear Street and Maxim raises max aggregate gross proceeds from $92.8M to $250.0M.
Solana Company Q1 revenue $3.6M, net loss $99.8M ($1.30/share) on digital asset write-downs
Q1 revenue $3.6M (primarily $3.4M staking rewards) vs $49K in Q1 2025; gross profit $3.4M.
HSDT raises $8M in registered direct offering; puts offer 7% IRR repurchase
Issued 3,076,922 shares at $2.60/share; net proceeds ~$7.9M.
Solana Company CMO Antonella Favit-Van Pelt departs with $875,000 separation payment
Dr. Favit-Van Pelt resigned as Chief Medical Officer effective April 8, 2026, under a mutual separation agreement.
Solana Q4 net income $325.6M ($4.25 EPS) on $5.2M revenue; $293.7M in SOL holdings
Q4 2025 revenue $5.2M (vs $0.2M prior year), driven by $5.1M staking rewards.
Solana (HSDT) Q3 net loss $352.8M; $500M+ SOL treasury partnership closed
Q3 net loss $352.8M ($32.89 loss per share) vs $3.7M loss a year ago; operating loss $35.5M vs $4.1M.
Solana Company OKs $100M share buyback; board changes announced
Board authorized $100M stock repurchase program; open-ended, open market & negotiated transactions.
Solana Company elects Pantera Capital's Cosmo Jiang to Board; highlights Solana network growth
Elected Cosmo Jiang, General Partner at Pantera Capital, to the Board of Directors effective November 3, 2025.
Over 2.3M SOL held (increase of ~0.1M since Oct 6); cash/stablecoins exceed $15M.
Solana Company auditor switches from Baker Tilly to CBIZ; prior reports flagged going concern
Baker Tilly US, LLP resigned as independent auditor on October 15, 2025; Audit Committee accepted.
Helius Medical renames to Solana Company; signs LOI with Solana Foundation for SOL treasury strategy
Company name changed to Solana Company effective Sept 29, 2025; ticker HSDT unchanged.
FDA 510(k) filed for PoNS stroke label expansion under Breakthrough Device Designation.
Helius Medical starts SOL treasury; holds 760,190 tokens at avg cost $231
First acquisition of SOL tokens as part of digital asset treasury strategy; principal holding will be SOL.
Raised $508.7M gross proceeds; potential total >$1.25B if all stapled warrants exercised at $10.134.
Helius raises $500M+ in PIPE to fund SOL treasury; Joseph Chee named Executive Chairman
Offering priced at $6.881/share + stapled warrants at $10.134; gross proceeds ~$500M cash, up to $1.25B total.
Helius Medical enters ATM sales agreement for up to $92.8M; authorizes 800M shares
Entered Sales Agreement with Clear Street and Maxim to sell up to $92.8M of Class A common stock in at-the-market offerings.
Helius Medical reports positive PoNS Stroke Registrational Program results; FDA submission planned
Double-blind RCT met primary endpoint: statistically significant improvements in gait/balance with active PoNS therapy (with/without open-label data).
Helius Medical regains full Nasdaq compliance; subject to one-year monitor
Received Nasdaq notification on July 7, 2025 confirming compliance with $2.5M stockholders' equity requirement.
Helius Medical Technologies files prospectus for up to $25M at-the-market stock offering
Filed updated Prospectus Supplement for sale of up to $25M of common stock.
Helius regains Nasdaq equity compliance with $6.6M equity after $8.1M offering
Stockholders' equity of $6.561M as of June 17, 2025, above Nasdaq's $2.5M minimum.
Helius regains Nasdaq bid price compliance; equity rule deadline June 30, 2025 remains
Regained compliance with Nasdaq minimum bid price rule (5550(a)(2)) as of June 3, 2025.
Helius announces 1-for-15 reverse stock split effective May 1 to maintain Nasdaq listing
Reverse split approved by board at 1-for-15 ratio, effective 5:00 pm ET on May 1, 2025.
Helius Medical raises $1.3M via 20% OID notes and 1.32M shares in private placement
Aggregate principal of $1.56M in 20% original issue discount promissory notes; gross proceeds $1.3M before fees.
Shareholders approve reverse stock split and warrant inducement at annual meeting
Elected six directors: Blane Walter (1,001,991 for), Dane Andreeff, Edward Straw, Jeffrey Mathiesen, Paul Buckman, Sherrie Perkins.
Helius Medical gets Nasdaq delisting warning for equity <$2.5M; extension to June 30, 2025
Received Nasdaq notice on March 31, 2025 for stockholders' equity below $2.5M from FY2024 10-K.
Helius Medical faces Nasdaq delisting; to appeal, sets 2025 annual meeting for April 21
Received Nasdaq delisting notice on Feb 7, 2025 for continued bid price below $1; intends to appeal, hearing stays delisting.
Aggregate gross proceeds of ~$3.7M from cash exercise of 4,971,110 existing warrants at reduced price of $0.751/share.
CMS finalizes Medicare payment rates for Helius' PoNS Controller (A4593)
CMS posted final DMEPOS fee schedule payment rates for PoNS Controller (HCPCS A4593) on Jan 13, 2025.
Helius initiates strategic alternatives review after unfavorable CMS pricing for PoNS device
Engaged B. Riley Securities to advise on strategic alternatives including merger, sale, or licensing.
Revenue $182K vs $256K YoY due to PTAP termination; up 35% sequentially from Q1 2024.
Helius Medical receives Nasdaq delisting notice for bid price below $1.00 for 30 days
Nasdaq letter dated Aug 9, 2024; compliance period until Feb 5, 2025 to regain minimum bid price.
Helius Medical regains Nasdaq compliance with $2.5M equity rule after May 9 financing
Received formal Nasdaq notice on May 31, 2024 confirming compliance with Listing Rule 5550(b)(1).
Helius Medical Q1 rev $135K (+22% YoY); net loss flat $2.5M; CMS PoNS reimbursement milestone
Q1 revenue $135K vs $111K YoY; operating loss $3.4M vs $3.8M, driven by lower professional fees and clinical trial costs.
Helius Medical prices $6.4M public offering of stock and warrants
Offering consists of 804,999 shares, 2,047,222 pre-funded warrants, and Series A/B warrants for up to 5.7M shares.
CMS proposes preliminary Medicare payment rates for PoNS: mouthpiece $3,075.53, controller $1,206.53
CMS preliminary DMEPOS fee schedule sets PoNS Mouthpiece (A4594) capped payment at $3,075.53 based on cash pay price of $4,500.
Helius Medical receives Nasdaq delisting notice for failing minimum equity requirement
Stockholders' equity fell below $2.5M as of Dec 31, 2023, triggering Nasdaq Listing Rule 5550(b)(1) non-compliance.
Helius Medical Q4 revenue down 52% YoY; net loss per share $1.47 vs $8.66
Q4 2023 revenue $134K, down from $282K in Q4 2022, due to US PTAP expiration and lower Canada sales.
Mr. Mitchell Tyler notified the Board of Directors (the “Board”) of Helius Medical Technologies, Inc. (the “Company”) of his intention to retire from service on the Board upon expiration of his current term
approved an increase in the size of the Board from five to six directors and the appointment of Paul Buckman to fill the vacancy created by such increase, which appointment became effective on September 10, 2021 upon Mr. Buckman’s acceptance.
the employment of Joyce LaViscount, Chief Operating Officer of Helius Medical Technologies, Inc. (the “Company”) ended on July 20, 2021
The employment of Joyce LaViscount, Chief Operating Officer of Helius Medical Technologies, Inc. ended on July 20, 2021.
Max materiality 1.00 · Median 0.65 · Most common event other_material